Summary

Leuprolide (leuprorelin) is a synthetic nonapeptide agonist of gonadotropin-releasing hormone (GnRH). With over 1,500 PubMed-indexed publications, it is one of the most extensively studied peptide therapeutics. Chronic administration paradoxically suppresses gonadotropin secretion, making it a key research tool for hormone-dependent conditions. It is a licensed POM in the UK.

Overview

Leuprolide acetate is a synthetic analogue of naturally occurring gonadotropin-releasing hormone (GnRH), a decapeptide produced in the hypothalamus. Leuprolide is a nonapeptide with modifications at positions 6 (D-leucine replacing glycine) and 10 (ethylamide replacing glycinamide), which increase potency and extend half-life relative to endogenous GnRH.

Originally synthesised in the 1970s, leuprolide has become one of the most widely prescribed peptide therapeutics globally. Its primary clinical applications are in hormone-dependent cancers (prostate, breast), endometriosis, uterine fibroids, and central precocious puberty. In the UK, it is available under brand names including Prostap, Lupron, and Eligard.

For research and educational purposes only. Leuprolide is a licensed POM in the UK.

Mechanism of Action

Leuprolide acts at GnRH receptors on the anterior pituitary gonadotrophs. Its mechanism has two phases:

  1. Initial stimulation (flare): Upon first administration, leuprolide stimulates a surge in luteinising hormone (LH) and follicle-stimulating hormone (FSH) release, transiently increasing gonadal steroid production (testosterone in males, oestradiol in females).

  2. Sustained suppression: With continuous (non-pulsatile) administration, GnRH receptors are downregulated and desensitised. Pituitary LH and FSH secretion falls dramatically, and gonadal steroid production drops to castrate levels. This is the basis for leuprolide's therapeutic effect in hormone-dependent conditions.

Reversibility: Upon discontinuation, pituitary-gonadal function typically recovers within weeks to months, depending on the duration of treatment.

The pulsatile versus continuous signalling paradigm was elucidated by Belchetz et al. (1978) in a landmark Science publication — pulsatile GnRH stimulates, while continuous GnRH suppresses the reproductive axis.

Research Summary

Evidence Grade: Strong

Leuprolide has extensive clinical evidence across multiple domains:

Prostate Cancer: The landmark study by Crawford et al. (1989) established leuprolide plus flutamide as a standard of care in advanced prostate cancer. Continuous leuprolide suppresses testosterone to castrate levels, inhibiting androgen-dependent tumour growth. Long-term follow-up studies confirm survival benefit equivalent to surgical orchiectomy.

Endometriosis: Multiple RCTs demonstrate leuprolide's efficacy in reducing endometriosis-associated pain through oestrogen suppression. The drug induces a reversible hypo-oestrogenic state that causes endometrial implants to atrophy.

Central Precocious Puberty: Leuprolide is a standard treatment for central precocious puberty (CPP), halting premature pubertal progression and preserving adult height potential.

Preclinical research: In laboratory research, leuprolide is used in hormone-sensitive tumour models (breast, prostate xenografts) and reproductive biology studies.

Key Studies

  1. Crawford ED et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. New England Journal of Medicine. 1989;321(7):419-424.
  2. Treatment of central precocious puberty with leuprolide. Journal of Clinical Endocrinology & Metabolism. 1990;70(1):181-186.
  3. Belchetz PE et al. Hypophyseal responses to continuous and intermittent delivery of hypothalamic GnRH. Science. 1978;202(4368):631-633.
  4. Limonta P et al. GnRH receptors in cancer: from cell biology to novel targeted therapeutic strategies. Endocrine Reviews. 2012;33(5):784-811.

Commonly Discussed Protocols

All information is for research and educational purposes only. Leuprolide is a licensed POM — no protocols for unsupervised use are provided.

In published clinical literature:

  • Depot injection: 3.75 mg monthly, 7.5 mg monthly, 11.25 mg every 3 months, 22.5 mg every 3 months, or 30 mg every 4 months (depending on indication and formulation)
  • Research dosing in animal models: Typically 0.1–1 mg/kg subcutaneously, with frequency depending on study design
  • In vitro research: 10 nM to 10 microM for cell culture studies on GnRH receptor-expressing lines

Stacking

No established research protocols combine leuprolide with other peptides. In clinical oncology, leuprolide is combined with anti-androgens (e.g., flutamide, bicalutamide) as combined androgen blockade, but this is outside the scope of research-peptide use.

Storage and Reconstitution

  • Storage: Store lyophilised leuprolide at 2-8 degrees C. Protect from light. Depot formulations have specific storage requirements per manufacturer instructions.
  • Reconstitution: Reconstitute with the diluent provided by the manufacturer. For laboratory research, dissolve in sterile bacteriostatic water or PBS.
  • Stability: Use reconstituted solutions promptly. Store at -20 degrees C for long-term research storage. Avoid repeated freeze-thaw cycles.

Blood Work

In clinical and research contexts involving leuprolide:

  • Testosterone (males) / Oestradiol (females): Monitor to confirm adequate suppression to castrate levels
  • LH and FSH: Monitor to verify pituitary suppression
  • Bone density: Long-term leuprolide use causes bone mineral density loss; DEXA monitoring is recommended
  • Lipid panel: Leuprolide may alter lipid profiles
  • PSA (males): Monitor prostate-specific antigen in oncology contexts
  • Calcium and vitamin D: Monitor for bone health during long-term suppression

UK Legal Status

Leuprolide is a licensed prescription-only medicine (POM) in the UK, regulated by the MHRA. It is available under brand names including Prostap, Lupron, and Eligard. It is not a controlled substance under the Misuse of Drugs Act.

Research-grade leuprolide for in vitro or laboratory research may be available from established chemical supply houses with appropriate purity documentation. Any use in humans without a prescription is illegal.

Vetted UK Vendors

As leuprolide is a licensed POM, it is not sold as a research peptide by the vetted vendors listed on Peptide Data. Researchers requiring leuprolide for legitimate laboratory research should source it through established chemical supply houses with HPLC-verified purity documentation.

References

  1. Crawford ED et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med. 1989;321(7):419-424. PMID: 2503724.
  2. Lee PA et al. Central precocious puberty treated with leuprolide. J Clin Endocrinol Metab. 1990;70(1):181-186.
  3. Belchetz PE et al. Hypophyseal responses to continuous and intermittent delivery of hypothalamic gonadotropin-releasing hormone. Science. 1978;202(4368):631-633.
  4. Limonta P et al. GnRH receptors in cancer: from cell biology to novel targeted therapeutic strategies. Endocr Rev. 2012;33(5):784-811.

References

  1. Crawford ED et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med. 1989;321(7):419-424. PMID: 2503724.
  2. Lee PA et al. Central precocious puberty treated with leuprolide. J Clin Endocrinol Metab. 1990;70(1):181-186.
  3. Belchetz PE et al. Hypophyseal responses to continuous and intermittent delivery of hypothalamic GnRH. Science. 1978;202(4368):631-633.
  4. Limonta P et al. GnRH receptors in cancer: from cell biology to novel targeted therapeutic strategies. Endocr Rev. 2012;33(5):784-811.